CLINICAL TRIALS PROFILE FOR ALDARA
✉ Email this page to a colleague
All Clinical Trials for Aldara
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00079300 ↗ | Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer | Completed | National Naval Medical Center | Phase 1 | 2004-01-01 | RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating patients with basal cell skin cancer. |
| NCT00142454 ↗ | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | Completed | American Society of Clinical Oncology | Phase 1 | 2005-08-24 | This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment. |
| NCT00142454 ↗ | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | Completed | Cancer Research Institute (CRI) | Phase 1 | 2005-08-24 | This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment. |
| NCT00142454 ↗ | NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting) | Completed | Ludwig Institute for Cancer Research | Phase 1 | 2005-08-24 | This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant melanoma. The primary study objective was to determine the safety of NY-ESO-1 protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity of treatment. |
| NCT00176943 ↗ | Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% | Completed | National Alopecia Areata Foundation | Phase 4 | 2000-10-01 | It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle. |
| NCT00176943 ↗ | Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% | Completed | Hordinsky, Maria K., MD | Phase 4 | 2000-10-01 | It is thought that alopecia areata occurs as the result of an inappropriate response of the body's own immune system to certain substances in or around the hair follicle. We will be examining the efficacy of Aldara Cream 5% in treating extensive alopecia areata and observe its affect on the hair follicle. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Aldara
Condition Name
Clinical Trial Locations for Aldara
Trials by Country
Clinical Trial Progress for Aldara
Clinical Trial Phase
Clinical Trial Sponsors for Aldara
Sponsor Name
